Bank of America spends $250M on GLP-1 drugs

Bank of America said on August 5 that it now spends more than $250 million a year on GLP-1 drugs for employees, putting a concrete number on a cost pressure that large U.S. employers have been discussing for months. CEO Brian Moynihan told CNBC the spending is part of the bank’s benefits program for its workforce of roughly 211,000 employees. The company’s total annual healthcare budget is more than $2 billion, he said. (cnbc.com) That means GLP-1 medicines alone now account for about 13% of the bank’s healthcare spending, based on figures he provided. ### How big is the GLP-1 bill inside Bank of America’s benefits budget? The $250 million figure is notable because it sits inside a healthcare budget that Moynihan said exceeds $2 billion a year. By that measure, the bank is devoting about one dollar out of every eight in healthcare spending to GLP-1 drugs. CNBC reported that the figure covers medications used for weight loss through employee benefits. (cnbc.com) Roughly 211,000 employees are covered by the bank’s overall healthcare program, according to CNBC’s report on Moynihan’s remarks. The size of that workforce helps explain why even a single drug category can become a nine-figure expense when uptake rises. ### What did Brian Moynihan say about why the bank is paying it? Moynihan told CNBC the spending is “a good investment,” even as he said the bank is pressing for lower prices. (cnbc.com) CNBC reported that he said, “Believe me, we’re pounding everybody on price,” while arguing that the drugs can produce long-term and possibly shorter-term health benefits for employees. The CNBC interview also framed the expense as a rapid change from recent years. Other reports citing the interview said Bank of America’s spending on the category was effectively zero four to five years ago, before employer coverage and demand expanded. ### Which drugs are part of this category? (cnbc.com) GLP-1 drugs include widely used diabetes and obesity treatments such as Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound, according to follow-on reports citing Moynihan’s comments. Employers have faced rising interest in those drugs as use has spread beyond diabetes treatment into obesity care. (gate.com) CNBC said the bank’s disclosure offers a rare employer-level figure for what that demand looks like in dollar terms. The report described the cost as rapidly rising, a point that has become central to benefit discussions as these medicines can cost thousands of dollars per patient each year. ### Why are employers watching numbers like this so closely? (ibtimes.com) Large employers have been weighing whether the upfront cost of GLP-1 coverage could be offset by lower medical spending later. Moynihan told CNBC he sees health benefits from the drugs and said that view supports the bank’s current spending. Business Insider, also citing his remarks, reported that he acknowledged some employees may leave before the company captures the full long-term payoff. (cnbc.com) That tension — high current cost against possible future savings — is now showing up in public through one of the country’s biggest banks. Bank of America’s disclosure gives benefits managers, drugmakers and investors a benchmark from a single large employer rather than an industry estimate. ### Where did the disclosure surface, and what comes next? (cnbc.com) CNBC published the interview with Moynihan on August 5 from Aspen, Colorado, where he discussed the bank’s healthcare spending and employee benefits. The next public markers are likely to come through future employer-benefits disclosures, drug-pricing negotiations and additional comments from large companies as 2027 healthcare budgets are set. (cnbc.com)